

#term ID	term description	observed gene count	background gene count	strength	false discovery rate
hsa04750	Inflammatory mediator regulation of TRP	9	92	2.2	5.15E-17
hsa04066	HIF-1 signaling pathway	8	98	2.12	8.69E-15
hsa04666	Fc gamma R-mediated phagocytosis	8	89	2.17	8.69E-15
hsa04933	AGE-RAGE signaling pathway in diabetic complications	8	98	2.12	8.69E-15
hsa04960	Aldosterone-regulated sodium reabsorption	7	37	2.49	8.69E-15
hsa05146	Amoebiasis	8	94	2.14	8.69E-15
hsa04930	Type II diabetes mellitus	7	46	2.39	1.04E-14
hsa04725	Cholinergic synapse	8	111	2.07	1.17E-14
hsa04071	Sphingolipid signaling pathway	8	116	2.05	1.46E-14
hsa04370	VEGF signaling pathway	7	59	2.29	3.68E-14
hsa05161	Hepatitis B	8	142	1.96	5.69E-14
hsa04072	Phospholipase D signaling pathway	8	145	1.95	6.13E-14
hsa04664	Fc epsilon RI signaling pathway	7	67	2.23	6.13E-14
hsa05223	Non-small cell lung cancer	7	66	2.24	6.13E-14
hsa05214	Glioma	7	68	2.22	6.24E-14
hsa01521	EGFR tyrosine kinase inhibitor resistance	7	78	2.17	1.44E-13
hsa05164	Influenza A	8	168	1.89	1.44E-13
hsa04012	ErbB signaling pathway	7	83	2.14	1.95E-13
hsa04151	PI3K-Akt signaling pathway	9	348	1.62	2.94E-13
hsa05205	Proteoglycans in cancer	8	195	1.83	3.67E-13
hsa04070	Phosphatidylinositol signaling system	7	97	2.07	4.74E-13
hsa05231	Choline metabolism in cancer	7	98	2.07	4.84E-13
hsa05142	Chagas disease (American trypanosomiasis)	7	101	2.05	5.67E-13
hsa04620	Toll-like receptor signaling pathway	7	102	2.05	5.81E-13
hsa04931	Insulin resistance	7	107	2.03	7.58E-13
hsa04973	Carbohydrate digestion and absorption	6	42	2.37	7.58E-13
hsa04670	Leukocyte transendothelial migration	7	112	2.01	9.68E-13
hsa04919	Thyroid hormone signaling pathway	7	115	2	1.12E-12
hsa04611	Platelet activation	7	123	1.97	1.70E-12
hsa04650	Natural killer cell mediated cytotoxicity	7	124	1.96	1.73E-12
hsa04923	Regulation of lipolysis in adipocytes	6	53	2.27	2.24E-12
hsa04926	Relaxin signaling pathway	7	130	1.94	2.24E-12
hsa05162	Measles	7	133	1.93	2.53E-12
hsa05213	Endometrial cancer	6	58	2.23	3.39E-12
hsa04213	Longevity regulating pathway - multiple species	6	61	2.21	4.38E-12
hsa04150	mTOR signaling pathway	7	148	1.89	4.78E-12
hsa05230	Central carbon metabolism in cancer	6	65	2.18	5.94E-12
hsa05221	Acute myeloid leukemia	6	66	2.17	6.31E-12
hsa05211	Renal cell carcinoma	6	68	2.16	7.28E-12
hsa04917	Prolactin signaling pathway	6	69	2.15	7.71E-12
hsa01524	Platinum drug resistance	6	70	2.15	8.08E-12
hsa05225	Hepatocellular carcinoma	7	163	1.85	8.08E-12
hsa04662	B cell receptor signaling pathway	6	71	2.14	8.45E-12
hsa05100	Bacterial invasion of epithelial cells	6	72	2.13	8.94E-12
hsa05218	Melanoma	6	72	2.13	8.94E-12

hsa05212	Pancreatic cancer	6	74	2.12	1.00E-11
hsa04360	Axon guidance	7	173	1.82	1.06E-11
hsa05220	Chronic myeloid leukemia	6	76	2.11	1.12E-11
hsa05167	Kaposi's sarcoma-associated herpesvirus infection	7	183	1.79	1.49E-11
hsa05210	Colorectal cancer	6	85	2.06	2.03E-11
hsa04510	Focal adhesion	7	197	1.76	2.36E-11
hsa04211	Longevity regulating pathway	6	88	2.05	2.39E-11
hsa04015	Rap1 signaling pathway	7	203	1.75	2.79E-11
hsa05222	Small cell lung cancer	6	92	2.03	2.97E-11
hsa04914	Progesterone-mediated oocyte maturation	6	94	2.02	3.30E-11
hsa01522	Endocrine resistance	6	95	2.01	3.44E-11
hsa05215	Prostate cancer	6	97	2	3.82E-11
hsa04660	T cell receptor signaling pathway	6	99	1.99	4.22E-11
hsa04014	Ras signaling pathway	7	228	1.7	5.53E-11
hsa04668	TNF signaling pathway	6	108	1.96	6.74E-11
hsa04722	Neurotrophin signaling pathway	6	116	1.93	1.00E-10
hsa04152	AMPK signaling pathway	6	120	1.91	1.20E-10
hsa04380	Osteoclast differentiation	6	124	1.9	1.43E-10
hsa04140	Autophagy - animal	6	125	1.89	1.47E-10
hsa04068	FoxO signaling pathway	6	130	1.88	1.82E-10
hsa05160	Hepatitis C	6	131	1.87	1.88E-10
hsa04915	Estrogen signaling pathway	6	133	1.87	2.02E-10
hsa05418	Fluid shear stress and atherosclerosis	6	133	1.87	2.02E-10
hsa04910	Insulin signaling pathway	6	134	1.86	2.05E-10
hsa04210	Apoptosis	6	135	1.86	2.11E-10
hsa04550	Signaling pathways regulating pluripotency of stem cells	6	138	1.85	2.36E-10
hsa05224	Breast cancer	6	147	1.82	3.36E-10
hsa05226	Gastric cancer	6	147	1.82	3.36E-10
hsa04932	Non-alcoholic fatty liver disease (NAFLD)	6	149	1.82	3.54E-10
hsa04218	Cellular senescence	6	156	1.8	4.57E-10
hsa04630	Jak-STAT signaling pathway	6	160	1.79	5.22E-10
hsa04062	Chemokine signaling pathway	6	181	1.73	1.06E-09
hsa05203	Viral carcinogenesis	6	183	1.73	1.11E-09
hsa05169	Epstein-Barr virus infection	6	194	1.7	1.55E-09
hsa04024	cAMP signaling pathway	6	195	1.7	1.57E-09
hsa04810	Regulation of actin cytoskeleton	6	205	1.68	2.08E-09
hsa05166	HTLV-I infection	6	250	1.59	6.57E-09
hsa05200	Pathways in cancer	7	515	1.35	1.03E-08
hsa05165	Human papillomavirus infection	6	317	1.49	2.57E-08
hsa00562	Inositol phosphate metabolism	4	73	1.95	1.66E-07
hsa05206	MicroRNAs in cancer	4	149	1.64	2.59E-06
hsa05143	African trypanosomiasis	2	34	1.98	0.00033
hsa05130	Pathogenic Escherichia coli infection	2	53	1.79	0.00075
hsa04925	Aldosterone synthesis and secretion	2	93	1.54	0.0022
hsa05145	Toxoplasmosis	2	109	1.48	0.003
hsa04270	Vascular smooth muscle contraction	2	119	1.44	0.0035
hsa04371	Apelin signaling pathway	2	133	1.39	0.0043
hsa04261	Adrenergic signaling in cardiomyocytes	2	139	1.37	0.0046

hsa04921	Oxytocin signaling pathway	2	149	1.34	0.0052
hsa04022	cGMP-PKG signaling pathway	2	160	1.31	0.0059